文献速递骨质疏松与代谢性骨病

全基因组基因组评分加入标准推荐分层工具未能改善极低骨密度患者的识别

A genome-wide genomic score added to standard recommended stratification tools does not improve the identification of patients with very low bone mineral density.
PubMed 文献 · Osteoporos Int · 2023-07-26

在1421名参与者中,通过CT测量三个胸椎骨密度,评估将基因组评分加入推荐分层工具是否改善极低骨密度(<80 mg/cm3)的判别。结果显示,基因组评分加入临床风险因素模型未显著改善预测或重分类;但基因组评分判别力等于或高于单个风险因素,而临床风险因素组合判别力优于单个风险因素和基因组评分。

要点

  • 在总队列(n=1421)中,基因组评分的AUC为0.57(95%CI 0.52-0.61),与骨质疏松风险因素的AUC相当。
  • 加入基因组评分后,临床风险因素模型的AUC无统计学显著改善,重分类分析亦无改善。
  • 临床风险因素组合的判别力优于单个风险因素和基因组评分,支持其作为常规分层工具的价值。

核心结论

  • 研究结果提示,将基因组评分加入临床风险因素模型并未改善对极低骨密度的预测。
  • 基因组评分在判别力上等于或高于单个风险因素,但临床风险因素组合的判别力优于单个风险因素和基因组评分。

研究设计与样本

  • 研究纳入1421名参与者,通过CT测量三个胸椎的骨密度,并收集标准骨质疏松风险因素信息。
  • 计算基因组评分和FRAX评分,根据平均骨密度将参与者分为极低(<80 mg/cm3)、低(80-120 mg/cm3)和正常(>120 mg/cm3)组,并按骨健康与骨质疏松基金会建议分为有骨密度检测指征和无指征组。
  • 使用受试者工作特征曲线下面积(AUC)和重分类分析评估不同模型。

主要发现

  • 在总队列(n=1421)中,基因组评分的AUC为0.57(95%CI 0.52-0.61)。
  • 在无骨密度检测指征的参与者中,基因组评分的AUC为0.60(95%CI 0.52-0.69),等于或高于骨质疏松风险因素的AUC。
  • 将基因组评分加入临床风险因素模型后,AUC与临床风险因素模型相比无统计学显著差异。
  • 使用6%、12%和24%的概率截断值,临床风险因素-基因组评分模型与临床风险因素模型相比,未发现重分类或风险判别改善。

临床怎么用

  • 作者认为,临床风险因素组合在常规临床中作为分层工具具有价值,因其判别力优于单个风险因素和基因组评分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The role of integrating genomic scores (GSs) needs to be assessed. Adding a GS to recommended stratification tools does not improve the prediction of very low bone mineral density. However, we noticed that the GS performed equally or above individual risk factors in discrimination. PURPOSE: We aimed to investigate whether adding a genomic score (GS) to recommended stratification tools improves the discrimination of participants with very low bone mineral density (BMD). METHODS: BMD was measured in three thoracic vertebrae using CT. All participants provided information on standard osteoporosis risk factors. GSs and FRAX scores were calculated. Participants were grouped according to mean BMD into very low (<80 mg/cm3), low (80-120 mg/cm3), and normal (>120 mg/cm3) and according to the Bone Health and Osteoporosis Foundation recommendations for BMD testing into an "indication for BMD testing" and "no indication for BMD testing" group. Different models were assessed using the area under the receiver operating characteristics curves (AUC) and reclassification analyses. RESULTS: In the total cohort (n=1421), the AUC for the GS was 0.57 (95% CI 0.52-0.61) corresponding to AUCs for osteoporosis risk factors. In participants without indication for BMD testing, the AUC was 0.60 (95% CI 0.52-0.69) above or equal to AUCs for osteoporosis risk factors. Adding the GS to a clinical risk factor (CRF) model resulted in AUCs not statistically significant from the CRF model. Using probability cutoff values of 6, 12, and 24%, we found no improved reclassification or risk discrimination using the CRF-GS model compared to the CRF model. CONCLUSION: Our results suggest adding a GS to a CRF model does not improve prediction. However, we noticed that the GS performed equally or above individual risk factors in discrimination. Clinical risk factors combined showed superior discrimination to individual risk factors and the GS, underlining the value of combined CRFs in routine clinics as a stratification tool.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Therkildsen J, Rohde PD, Nissen L, et al. A genome-wide genomic score added to standard recommended stratification tools does not improve the identification of patients with very low bone mineral density. Osteoporos Int. 2023. PMID: 37495683. doi:10.1007/s00198-023-06857-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。